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Several points need to be clarified with regard to the news article
by Day.1 Most importantly, Italy’s new national immunisation
plan, issued by a working group of the ItalianMinistry of Health,
was built on the best available scientific evidence.
The four scientific societies that in 2014 released the second
edition of the “lifetime immunization schedule,”2 mentioned in
the news article, were consulted by the working group for
technical and scientific support. In particular, representatives
of the Italian Society of Hygiene, Preventive Medicine and
Public Health; the Italian Society of Pediatrics; the Italian
Federation of Community Pediatricians; and the Italian
Federation of General Practitioners were invited to two formal
hearings.Moreover, although the lifetime immunisation schedule
constituted a solid basis for discussion during the drafting of
the new plan, not all immunisation programmes that it
recommended were included in the plan (such as the
recommendation to decrease the age threshold for universal free
influenza immunisation to age 50 years).
The working group found convincing evidence and
pharmacoeconomic data supporting the efficacy, effectiveness,
and safety of the newly proposed vaccination programmes. For
example:
• Scientific data supported the great potential of human
papillomavirus (HPV) immunisation in males to protect
against several cancers in both sexes3
• Vaccination against rotavirus is offered to all newborns in
many European countries whose authorities have
considered its optimal cost effectiveness profile4
• Pneumococcal conjugate vaccination in at risk categories
and in selected age based cohorts of older people is already
offered in half of Italian regions on the basis of robust
scientific evidence.5
Day does not mention that on 15 October 2015 the technical
board of the State Regions Conference, whose members
represent all Italian regions, released a formal positive position
statement on the new national immunisation plan draft issued
by the ministry of health. Italian immunisation coverage rates
have been decreasing since 2012 and are still below national
targets,6 with a high degree of heterogeneity across different
regions and different vaccines. For example, in PiedmontMMR
(measles, mumps, and rubella) vaccine coverage does not reach
90% for the first dose (the WHO target is 95%) and HPV
vaccination does not reach the 70% minimum target coverage
for all invited birth cohorts.6
A comprehensive framework of immunisation policies in Italy
should have mentioned that, because some Italian regions have
already adopted the immunisation offer included in the new
plan, its adoption at the national level is a powerful tool to
harmonise immunisation strategies across the regions. Ultimately
it should ensure equity in access to prevention of infectious
diseases to all citizens. Currently, there are no differences in
the burden of infectious diseases across the Italian regions that
could justify different immunisation strategies.
Last but not least, economic aspects deserve a comment. In
recent years, Italy has not been able to invest 5% of total health
expenditure in prevention, as had been planned. This missing
investment needs to be considered when allocating resources.
The estimated increase of the total immunisation bill associated
with the new plan (€200-300m; £145-217m; $220-330m) is
barely 0.002% of total Italian health expenditure and 0.04% of
current expenditure for prevention services. In addition, the new
plan’s budget complements the new immunisation offer
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endorsing and transposing recent EU recommendations in terms
of strengthening healthcare providers’ training, health education
interventions, and immunisation services, as well as
implementing immunisation registries at the national level.7
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